Clinical research

Trust launches a new clinical trial for cystic fibrosis patients

Royal Papworth Hospital NHS FT has launched phase II of the clinical trial for patients with cystic fibrosis with serious lung infections, such as Mycobacterium abscessus. The trial aims to reduce the amount of mycobacteria, by using a solution which releases nitric oxide into the upper airways and deep alveolar spaces of the lungs. The method is to help kill viruses and bacteria and boost a person’s immune response.

Clinical trials are expected to start soon – with the nebulised nitric oxide generating solution (RESP301) - administered via a handheld nebuliser. Laboratory testing has shown strong activity against many bacterial species including M. abscessus, as well as viruses such as various influenza and coronavirus strains. 

The study – known as NOMAB – will treat patients with RESP301 over a 28-day period, aiming to measure the changes in the amount of mycobacteria in the lungs before and after treatment. It will also analyse whether there are any improvements in lung function.

Professor Andres Floto, the Research Director of the Cambridge Centre for Lung Infection (CCLI), Professor of Respiratory Biology at the University of Cambridge, and co-chief investigator for the study, said: “Infection with M. abscessus is a major problem for people with cystic fibrosis, is very difficult to treat, leads to accelerated lung damage, and can prevent safe lung transplantation.”

Dr Charles Haworth, co-chief investigator for the study and a respiratory consultant at the CCLI at the trust, added: “Lung infections in people with cystic fibrosis are becoming harder to treat due to the increasing prevalence of multi-drug resistant organisms such as M. abscessus. We urgently need new and effective approaches to combat these infections.”

There will initially be 12 subjects recruited, and if successful, expanded to a larger trial, broadening the scope of RESP301 in cystic fibrosis and other lung conditions. 

The study will be conducted at the trust, one of the UK’s leading centres for cystic fibrosis.

NHE July/August 21

NHE July/August 21

Prioritising staff wellbeing

NHE’s July/August 2021 edition focuses on some of the key, defining aspects of a successful, supported health service: Mental Health & Workforce. Elsewhere, we take on the incredibly topical Infection Prevention and address the role which Pharma will play in both our NHS and wider health environment.

Videos...

View all videos
National Health Executive Presents

National Health Executive Presents

NHE365 Virtual Festival: Net-Zero NHS

As was outlined by Sir Simon Stevens when the NHS announced their green plans back in 2020, 5,700 lives could be saved each year by improved air quality. Even more could see their overall health improve and be in a position to self-manage their conditions, rather than requiring NHS treatment. Covid-19 has already left the NHS with a sizeable treatment backlog, so anything which can be done to improve patient health and reduce demand is beneficial for all.

Working together, we can help the NHS realise its green ambitions as per the Net-Zero National Health Service report and its ambitious 2040 target. Join us on August 25, 2021 for our Net-Zero NHS event, where we will be joined by health sector leaders and innovators for a day of sharing best practice and networking.

Finger on the Pulse

Ep 14. Health messaging is a science, Professor Craig Jackson

On Episode 14 of NHE's Finger on the Pulse podcast, we're joined by Professor Craig Jackson, Professor of Occupational Health Psychology
Birmingham City University to discuss the coronavirus pandemic, the health messaging around it and how those in power have missed a trick by overlooking the key role of psychology in informing the public of restrictions, measures and the ever-changing situation

More articles...

View all